The COVID-19 pandemic, caused by SARS-CoV-2 virus, has resulted in unprecedented crisis to the global health. The SARS-CoV-2 has spread into over 188 countries and sickened over 78M people worldwide. A timely response to virus outbreaks in terms of the developments of both diagnostic tools and therapeutics is essential to combat such invisible enemies. To support these studies, Sino Biological has developed a comprehensive panel of antibodies and antigens for SARS-CoV-2. Sino Biological also specializes in recombinant antigen and antibody production. The ProVirTM collection is the world largest viral antigen bank, including over 800 proteins from 350 viral strains.
Up to 15th October, there are 284 publications that have cited SARS-CoV-2 reagents or services providing by Sino Biological Inc.
1. Cao, L,et al.De novo design of picomolar SARS-CoV-2 miniprotein inhibitors.Science (New York, N.Y.).2020
2. Hansen, J,et al.Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.Science (New York, N.Y.).2020
3. Chandrashekar, A,et al.SARS-CoV-2 infection protects against rechallenge in rhesus macaques.Science (New York, N.Y.).2020
4. Chan, KK,et al.Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2.Science.2020
5. Gu, H,et al.Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy.Science.2020
6. Deng, W,et al.Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques.Science.2020
7. Brouwer, PJM,et al.Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability.Science.2020
8. Renhong Yan,et al.Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2.Science.2020
9. Lamers, MM,et al.SARS-CoV-2 productively infects human gut enterocytes.Science.2020
10. Rockx, B,et al.Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model.Science.2020
11. Yu, J,et al.DNA vaccine protection against SARS-CoV-2 in rhesus macaques.Science.2020
12. Xiangyang Chi,et al.A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.Science.2020
13. Zhe Lv,et al.Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent theraprutic antibody.Science.2020
14. Bin Ju,et al.Human neutralizing antibodies elicited by SARS-CoV-2 infection.Nature.2020
15. Linlin Bao,et al.The Pathogenicity of SARS-CoV-2 in hACE2 Transgenic Mice.Nature.2020
16. Dora Pinto,et al.Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.Nature.2020
17. Bojkova, D,et al.Proteomics of SARS-CoV-2-infected host cells reveals therapy targets.Nature.2020
18. Liu, L,et al.Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike.Nature.2020
19. Ke, Z,et al.Structures and distributions of SARS-CoV-2 spike proteins on intact virions.Nature.2020
20. Meckiff, B,et al.Imbalance of regulatory and cytotoxic SARS-CoV-2-reactive CD4+ T cells in COVID-19.Cell.2020
21. Piccoli, L,et al.Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.Cell.2020
22. Yurkovetskiy, L,et al.Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant.Cell.2020
23. Du, S,et al.Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy.Cell.2020
24. Li, W,et al.High potency of a bivalent human VH domain in SARS-CoV-2 animal models.Cell.2020
25. Cao, Y,et al.Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients\' B cells.Cell.2020
26. Wrapp, Daniel,et al.Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies.Cell.2020
27. Sun, J,et al.Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment.Cell.2020
28. Wang, H,et al.Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2.Cell.2020
29. Dai, L,et al.A universal design of betacoronavirus vaccines against COVID-19, MERS and SARS.Cell.2020
30. Li, Q,et al.The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity.Cell.2020
31. Zhang, N,et al.A thermostable mRNA vaccine against COVID-19.Cell.2020
32. Chi, X,et al.Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain.Nature communications.2020
33. Rudberg, AS,et al.SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden.Nature Communications .2020
34. Simon, D,et al.Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversion.Nature Communications .2020
35. Jiang, HW,et al.SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses.Nature Communications .2020
36. Wang, C,et al.A human monoclonal antibody blocking SARS-CoV-2 infection.Nature Communications .2020
37. Ou, X,et al.Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV.Nature Communications .2020
38. Deng, W,et al.Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in Rhesus macaques.Nature Communications .2020
39. Smith, TRF,et al.Immunogenicity of a DNA vaccine candidate for COVID-19.Nature Communications .2020
40. Noy-Porat, T,et al.A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes.Nature Communications .2020
41. Zhao, H,et al.A broad-spectrum virus- and host-targeting peptide against respiratory viruses including influenza virus and SARS-CoV-2.Nature Communications .2020
42. Feng, L,et al.An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques.Nature Communications .2020
43. Ripperger, T,et al.Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low Prevalence Communities and Reveal Durable Humoral Immunity..Immunity.2020
44. Ni, L,et al.Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals.Immunity.2020
45. Laczkó, D,et al.A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice.Immunity.2020
46. Tostanoski, LH,et al.Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters.Nature Medicine.2020
47. Long, QX,et al.Antibody responses to SARS-CoV-2 in patients with COVID-19.Nature Medicine.2020
48. Amanat F,et al.A serological assay to detect SARS-CoV-2 seroconversion in humans.Nature Medicine.2020
49. McCallum, M,et al.Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation.Nat. Struct. Mol. Biol.2020
50. Wu, Y,et al.Identification of Human Single-Domain Antibodies against SARS-CoV-2.Cell Host Microbe.2020
51. Dieterle, M,et al.A replication-competent vesicular stomatitis virus for studies of SARS-CoV-2 spike-mediated cell entry and its inhibition.Cell Host & Microbe.2020
52. Stanifer, ML,et al.Critical Role of Type III Interferon in Controlling SARS-CoV-2 Infection in Human Intestinal Epithelial Cells.Cell Rep.2020
53. Zhang, H,et al.Activation of Peroxiredoxin 1 by Fluvastatin Effectively Protects from Inflammation and SARS-CoV-2.Cell Metabolism.2020
54. Huibin LvCross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections.Cell Reports.2020
55. Yi, C,et al.Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.Cell. Mol. Immunol.2020
56. Schurink, B,et al.Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study.The Lancet Microbe.2020
57. Matschke, J,et al.Neuropathology of patients with COVID-19 in Germany: a post-mortem case series.Lancet Neurol.2020
58. Xiao, F,et al.Evidence for gastrointestinal infection of SARS-CoV-2.Gastroenterology.2020
59. Seo, G,et al.Rapid Detection of COVID-19 Causative Virus (SARS-CoV-2) in Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based Biosensor.ACS Nano.2020
60. Su, H,et al.Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China.Kidney Int..2020
61. Ye, L,et al.Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor.Cellular & Molecular Immunology.2020
62. Bing ZhaoRecapitulation of SARS-CoV-2 Infection and Cholangiocyte Damage with Human Liver Organoids.Protein&Cell.2020
63. Chia, WN,et al.Serological differentiation between COVID-19 and SARS infections.Emerg Microbes Infect.2020
64. Sun B,et al.Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients.Emerg Microbes Infect..2020
65. Shan-Meng Lin,et al.Structure-Based Stabilization of Non-native Protein-Protein Interactions of Coronavirus Nucleocapsid Proteins in Antiviral Drug Design.J. Med. Chem.2020
66. Liu, X,et al.Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction.Acta Pharm Sin B.2020
67. Liu, X,et al.Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19.Acta Pharm Sin B.2020
68. Okba, NMA,et al.Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients.Emerging Infect. Dis.2020
69. Sangeun Jeon,et al.Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs.Antimicrob Agents Chemother.2020
70. Zeng, W,et al.Biochemical characterization of SARS-CoV-2 nucleocapsid protein.Biochemical and Biophysical Research Communications.2020
71. Fujita, R,et al.Efficient production of recombinant SARS-CoV-2 spike protein using the baculovirus-silkworm system.Biochemical and Biophysical Research Communications.2020
72. Chen, Z,et al.A DNA Aptamer Based Method for Detection of SARS-CoV-2 Nucleocapsid Protein.Virol Sin.2020
73. Huang, S,et al.Assessing the application of a pseudovirus system for emerging SARS-CoV-2 and re-emerging avian influenza virus H5 subtypes in vaccine development.Biomedical Journal.2020
74. Musarrat, F,et al.The anti-HIV Drug Nelfinavir Mesylate (Viracept) is a Potent Inhibitor of Cell Fusion Caused by the SARSCoV-2 Spike (S) Glycoprotein Warranting further Evaluation as an Antiviral against COVID-19 infections.J Med Virol.2020
75. Pu, T,et al.Evaluate Severe Acute Respiratory Syndrome Coronavirus 2 Infectivity by Pseudoviral Particles.J. Med. Virol.2020
76. Carnevale, S,et al.Direct endothelial damage and vasculitis due to SARS-CoV-2 in small bowel submucosa of CoViD-19 patient with diarrhea.J. Med. Virol.2020
77. Zeng, X,et al.Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy.Antibody Therapeutics.2020
78. Sobrevilla, JMV;¿ Por qué los pacientes con diabetes o hipertensión son más susceptibles a tener COVID-19?.Conference.2020
79. Harcourt, Jennifer,et al.Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States.Emerging Infectious Diseases.2020
80. Feng, Siqin,et al.Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein.Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases.2020
81. Zeng, X,et al.Molecular Detection of SARS-CoV-2 in Formalin Fixed Paraffin Embedded Specimens.JCI Insight.2020
82. Larsen, CP,et al.Collapsing Glomerulopathy in a Patient With Coronavirus Disease 2019 (COVID-19).Kidney Int Rep.2020
83. Simon, D,et al.Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 infection.Research Square.2020
84. Kanjanasirirat, P,et al.High-Content Screening of Thai Medicinal Plants Reveals Boesenbergia rotunda Extract and its Component Panduratin A as Anti-SARS-CoV-2 Agents.Research Square.2020
85. Yang, J,et al.Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor.Research Square.2020
86. Bdr-Eldeen, O;What we should understand about SARS-COV-2 GENOME..researchgate.net.2020
87. Ravichandran, Supriya,et al.Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits.Science Translational Medicine.2020
88. Zhou, R,et al.Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses.SSRN Journal.2020
89. Cheng, Y,et al.Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects.SSRN Journal.2020
90. 彭浩然,et al.上海 2 株严重急性呼吸综合征冠状病毒 2 的分离与鉴定.第二军医大学学报.2020
91. Yu, P,et al.Age-related rhesus macaque models of COVID-19.Anim Models Exp Med.2020
92. Turista, D,et al.Distribution of COVID-19 and Phylogenetic Tree Construction of SARS-CoV-2 in Indonesia.J. Pure Appl. Microbiol.2020
93. Belete, T;A review on Promising vaccine development progress for COVID-19 disease.Vacunas.2020
94. Gan, JH;Discovery of small molecule therapeutics for the Middle Eastern respiratory syndrome-coronavirus (MERS-CoV).Thesis.2020
95. Wang, C,et al.Alveolar macrophage dysfunction and cytokine storm in the pathogenesis of two severe COVID-19 patients.EBioMedicine.2020
96. Lei, H,et al.SARS-CoV-2 environmental contamination associated with persistently infected COVID-19 patients.Influenza Other Respir Viruses.2020
97. Hernandez, J,et al.Dodging COVID-19 infection: Low expression and localization of Angiotensin-Converting Enzyme 2 (ACE2) and Transmembrane Serine Protease 2 (TMPRSS2) in Mesenchymal Stem Cells derived from human umbilical cord (hUC-MSCs)..Research Square.2020
98. Wu, S,et al.A single dose of an adenovirus-vectored vaccine provides complete protection of the upper and lower respiratory tracts against SARS-CoV-2 challenge.Research Square.2020
99. Liu, L;Clinical and pathological findings of SARS-CoV-2 infection and concurrent IgA nephropathy: A case report.Research Square.2020
100. Ren, L,et al.The Kinetics of Humoral Response and its Relationship with the Disease Severity in COVID-19.Research Square.2020
101. Tang, X,et al.Spike protein up-regulates inflammatory axis of both thromboinflammation and leukotriene in severe COVID-19.Research Square.2020
102. Zhang, X,et al.Engineering mesenchymal stem cells with neutralizing and anti- inflammation dual-capability against SARS-CoV-2 infection.Research Square.2020
103. Ahmadivand, A,et al.Femtomolar-level detection of SARS-CoV-2 spike proteins using toroidal plasmonic metasensors.arXiv preprint.2020
104. 彭浩然,et al.严重急性呼吸综合征冠状病毒 2 假病毒的制备及验证.第二军医大学 .2020
105. Ratajczak, MZ,et al.SARS-CoV-2 Entry Receptor ACE2 Is Expressed on Very Small CD45- Precursors of Hematopoietic and Endothelial Cells and in Response to Virus Spike Protein Activates the Nlrp3 Inflammasome.Stem Cell Rev Rep.2020
106. Hu, J,et al.Development of cell-based pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2.Genes & Diseases.2020
107. Xu, L,et al.COVID-19-like symptoms observed in Chinese tree shrews infected with SARS-CoV-2.Zool Res.2020
108. Wang, Y,et al.SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen.J. Med. Virol.2020
109. Chiuppesi, F,et al.Development of a Multi-Antigenic SARS-CoV-2 Vaccine Using a Synthetic Poxvirus Platform.Res Sq.2020
110. Kumar, D,et al.Prospective Observational Study of Screening Asymptomatic Healthcare Workers for SARS-CoV-2 at a Canadian Tertiary Care Center.medRxiv.2020
111. Cate, D,et al.Antibody Screening Results for Anti-Nucleocapsid Antibodies Towards the Development of a SARS-CoV-2 Nucleocapsid Protein Antigen Detecting Lateral Flow Assay.ChemRxiv.2020
112. Feng, Z,et al.Detection of the SARS-CoV-2 Nucleocaspid Protein (NP) Using Immunohistochemistry.BIO-PROTOCOL.2020
113. Tosif, S,et al.Immune responses to SARS-CoV-2 in children of parents with symptomatic COVID-19.Research Square.2020
114. Brocato, RL,et al.Disruption of Adaptive Immunity Enhances Disease in SARS-CoV-2 Infected Syrian Hamsters.Research Square.2020
115. Gorshkov, K,et al.Quantum Dot-Conjugated SARS-CoV-2 Spike Pseudo-Virions Enable Tracking of Angiotensin Converting Enzyme 2 Binding and Endocytosis.ACS Nano.2020
116. Tan, X,et al.Rapid and quantitative detection of SARS-CoV-2 specific IgG for convalescent serum evaluation.Biosensors and Bioelectronics.2020
117. Al-Dalahmah, O,et al.Neuronophagia and microglial nodules in a SARS-CoV-2 patient with cerebellar hemorrhage.Acta Neuropathol Commun.2020
118. McAndrews, KM,et al.Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications on COVID-19 immunity.JCI Insight.2020
119. van Tol, S,et al.Accurate Serology for SARS-CoV-2 and common Human Coronaviruses using a Multiplex Approach.Emerg Microbes Infect.2020
120. Li, Y,et al.SARS-CoV-2 and three related coronaviruses utilize multiple ACE2 orthologs and are potently blocked by an improved ACE2-Ig.J. Virol..2020
121. Wang, N,et al.Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus.Phytomedicine.2020
122. Saha, R,et al.Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19.Front. Pharmacol..2020
123. Mirzaei, R,et al.Overview of the current promising approaches for the development of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine.Int. Immunopharmacol..2020
124. Xiao, C,et al.Human post-infection serological response to the spike and nucleocapsid proteins of SARS-CoV-2.Influenza Other Respir Viruses.2020
125. Wheeler, SE,et al.Evaluation of SARS-CoV-2 prototype serologic test in hospitalized patients.Clin. Biochem.2020
126. Li, N,et al.Molecular diagnosis of COVID‑19: Current situation and trend in China (Review).Exp Ther Med.2020
127. Yang, R,et al.Development and effectiveness of Pseudotyped SARS-CoV-2 system as determined by neutralizing efficiency and entry inhibition test in vitro.Biosaf Health.2020
128. Liu, L,et al.Subunit Nanovaccine with Potent Cellular and Mucosal Immunity for COVID-19.ACS Appl. Bio Mater..2020
129. Wang, G,et al.Degradation of SARS-CoV-2 Receptor ACE2 by Tobacco Carcinogens.SSRN Journal.2020
130. Liu, Z,et al.The recombinant subunit vaccine RBD-Fc, consisting of SARS-CoV-2 RBD and human IgG Fc as an immunopotentiator, elicits robust neutralizing antibody responses against SARS-CoV-2 infection.Research Square.2020
131. Azad, T,et al.Nanoluciferase complementation-based biosensor reveals the importance of N- linked glycosylation of SARS-CoV-2 Spike for viral entry.Research Square.2020
132. Grant, BD,et al.A SARS-CoV-2 Coronavirus Nucleocapsid Protein Antigen-Detecting Lateral Flow Assay.ChemRxiv.2020
133. Renn, A,et al.Fruitful neutralizing antibody pipeline brings hope to defeat SARS-Cov-2.Trends in Pharmacological Sciences.2020
134. Ko, M,et al.Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells.J. Med. Virol.2020
135. Hsu, A,et al.Placental SARS-CoV-2 in a Pregnant Woman with Mild COVID-19 Disease.J. Med. Virol.2020
136. Ko, CJ,et al.Perniosis during the COVID-19 pandemic: Negative Anti-SARS-CoV-2 Immunohistochemistry in Six Patients and Comparison to Perniosis Before the Emergence of SARS-CoV-2.J. Cutan. Pathol..2020
137. Schasfoort, R,et al.Presence and strength of binding of IgM, IgG and IgA antibodies against SARS-CoV-2 during CoViD-19 infection.Research Square.2020
138. pandolfi, l,et al.Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome.Research Square.2020
139. Gupta, Y,et al.Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening and in vitro assays.Research Square.2020
140. Zeng, C,et al.Leveraging mRNA Sequences and Nanoparticles to Deliver SARS-CoV-2 Antigens In Vivo.Adv. Mater. Weinheim.2020
141. Yu, J,et al.Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition.Blood.2020
142. Schäfer, R,et al.Human Mesenchymal Stromal Cells are resistant to SARS-CoV-2 Infection under Steady State, Inflammatory Conditions and in the Presence of SARS-CoV-2 infected Cells.Stem Cell Reports.2020
143. Xiong, HL,et al.Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cells.Emerg Microbes Infect.2020
144. Zhang, Q,et al.A serological survey of SARS-CoV-2 in cat in Wuhan.Emerg Microbes Infect.2020
145. Gianotti, R,et al.Similarities in Cutaneous Histopathological Patterns between COVID-19-positive and COVID-19 High-risk Patients with Skin Dermatosis.Acta Derm. Venereol..2020
146. Azad, T,et al.Implications for SARS-CoV-2 Vaccine Design: Fusion of Spike Glycoprotein Transmembrane Domain to Receptor-Binding Domain Induces Trimerization.Membranes (Basel).2020
147. McGregor, R,et al.Collaborative networks enable the rapid establishment of serological assays for SARS-CoV-2 during nationwide lockdown in New Zealand.PeerJ.2020
148. Diorio, C,et al.Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome.Pediatr Blood Cancer.2020
149. Demers-Mathieu, V,et al.Difference in levels of SARS-CoV-2 S1 and S2 subunits- and nucleocapsid protein-reactive SIgM/IgM, IgG and SIgA/IgA antibodies in human milk.J Perinatol.2020
150. Lee, SY,et al.A Novel Neutralizing Antibody Targeting Receptor Binding Domain of SARS-CoV-2.Research Square.2020
151. Cantera, J,et al.Screening Antibodies Raised Against the Spike Glycoprotein of SARS-CoV-2 to Support the Development of Rapid Antigen Assays.ChemRxiv.2020
152. Norman, M,et al.Ultrasensitive high-resolution profiling of early seroconversion in patients with COVID-19.Nature biomedical engineering.2020
153. Pierce, CA,et al.Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients.Science translational medicine.2020
154. Segalés, J,et al.Detection of SARS-CoV-2 in a cat owned by a COVID-19-affected patient in Spain.Proceedings of the National Academy of Sciences of the United States of America.2020
155. Cazares, LH,et al.Development of a parallel reaction monitoring (PRM) mass spec-trometry-assay for the detection of SARS-CoV-2 spike glycoprotein and nucleoprotein.Anal. Chem..2020
156. Lee, S,et al.Robust and persistent SARS-CoV-2 infection in the human intestinal brush border expressing cells.Emerg Microbes Infect.2020
157. Jin, W,et al.The structure-activity relationship of the interactions of SARS-CoV-2 spike glycoproteins with glucuronomannan and sulfated galactofucan from Saccharina japonica.International journal of biological macromolecules.2020
158. Rayner, JO,et al.AR12 (OSU-03012) suppresses GRP78 expression and inhibits SARS-CoV-2 replication.Biochemical pharmacology.2020
159. Yu, S,et al.Glycyrrhizic Acid Exerts Inhibitory Activity against the Spike Protein of SARS-CoV-2.Phytomedicine.2020
160. Omotuyi, IO,et al.Aframomum melegueta secondary metabolites exhibit polypharmacology against SARS-CoV-2 drug targets: in vitro validation of furin inhibition.Phytother Res.2020
161. Liu, X,et al.Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.Vaccine.2020
162. Ko, CJ,et al.Discordant anti-SARS-CoV-2 spike protein and RNA staining in cutaneous perniotic lesions suggests endothelial deposition of cleaved spike protein.Journal of cutaneous pathology.2020
163. Oishee, M,et al.COVID-19 diagnostics: Current and Prospective Tools.Journal of Translational Autoimmunity.2020
164. Dong, J,et al.Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2.Research Square.2020
165. Tao, W,et al.Analysis of the intestinal microbiota in COVID-19 patients and its correlation with the inflammatory factor IL-18.Medicine in Microecology.2020
166. Jacob, F,et al.Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus Epithelium.Cell Stem Cell.2020
167. Liu, Q,et al.Pathological changes in the lungs and lymphatic organs of twelve COVID-19 autopsy cases.National Science Review.2020
168. Zeng, H,et al.The efficacy assessment of convalescent plasma therapy for COVID-19 patients: a multi-center case series.Signal Transduct Target Ther.2020
169. Lee, J,et al.A novel rapid detection for SARS-CoV-2 spike 1 antigens using human angiotensin converting enzyme 2 (ACE2).Biosensors and Bioelectronics.2020
170. Cady, N,et al.Multiplexed detection and quantification of human antibody response to COVID-19 infection using a plasmon enhanced biosensor platform.Biosensors and Bioelectronics.2020
171. Rao, L,et al.Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines.Proc Natl Acad Sci U S A.2020
172. Bosco-Lauth, AM,et al.Experimental infection of domestic dogs and cats with SARS-CoV-2: Pathogenesis, transmission, and response to reexposure in cats.Proc Natl Acad Sci U S A.2020
173. Chen, X,et al.Identifying potential anti-COVID-19 pharmacological components of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening.Acta Pharmaceutica Sinica B.2020
174. Li, H,et al.Establishment of replication-competent vesicular stomatitis virus-based recombinant viruses suitable for SARS-CoV-2 entry and neutralization assays.Emerg Microbes Infect.2020
175. Luetkens, T,et al.Successful transfer of anti-SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19.Blood Adv.2020
176. Hopfer, H,et al.Hunting coronavirus by transmission electron microscopy - a guide to SARS-CoV-2-associated ultrastructural pathology in COVID-19 tissues.Histopathology.2020
177. Alandijany, TA,et al.Development and Optimization of In-house ELISA for Detection of Human IgG Antibody to SARS-CoV-2 Full Length Spike Protein.Pathogens.2020
178. Barisione, E,et al.Fibrotic progression and radiologic correlation in matched lung samples from COVID-19 post-mortems.Virchows Arch.2020
179. Huang, PH,et al.Neutralizing antibody response elicited by SARS-CoV-2 receptor-binding domain.Hum Vaccin Immunother.2020
180. Torrente-Rodríguez, RM,et al.SARS-CoV-2 RapidPlex: A Graphene-based Multiplexed Telemedicine Platform for Rapid and Low-Cost COVID-19 Diagnosis and Monitoring.Matter.2020
181. Rosenke, K;Hansen, F,et al.Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model.Research Square.2020
182. Bullen, CK,et al.Infectability of human BrainSphere neurons suggests neurotropism of SARS-CoV-2.ALTEX.2020
183. Kim, SY,et al.Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions.Antiviral Res.2020
184. Takeda, Y,et al.Saxifraga spinulosa-Derived Components Rapidly Inactivate Multiple Viruses Including SARS-CoV-2.Viruses.2020
185. Yee, JL,et al.SARS-CoV-2 surveillance for a non-human primate breeding research facility.J. Med. Primatol..2020
186. Li, Z,et al.Cell-Mimicking Nanodecoys Protect Lung Cells by Neutralization of SARS-CoV-2 Spike Proteins.Research Square.2020
187. Wang, Z,et al.COVID-19 Severity Correlates with Weaker T Cell Immunity, Hypercytokinemia and Lung Epithelium Injury.Am. J. Respir. Crit. Care Med..2020
188. Tzankov, A,et al.Unlocking the lockdown of science and demystifying COVID-19: how autopsies contribute to our understanding of a deadly pandemic.Virchows Arch..2020
189. Chen, W,et al.Reducing false negatives in COVID-19 testing by using microneedle-based oropharyngeal swabs.Matter.2020
190. Chandrasekar, SS,et al.A Novel Mucosal Adjuvant System for Immunization against Avian Coronavirus Causing Infectious Bronchitis.J. Virol..2020
191. Prasad, ASV;Local Immunity Concept in the Context of the Novel Corona Viral Infection: A Consideration.bioRxiv.2020
192. Khan, S,et al.Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray.BioRxiv.2020
193. Thornburg, N,et al.Isolation and characterization of SARS-CoV-2 from the first US COVID-19 patient.bioRxiv.2020
194. Chunyun Sun,et al.SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development.bioRxiv.2020
195. Milewska, A,et al.HTCC as a highly effective polymeric inhibitor of SARS-CoV-2 and MERS-CoV.bioRxiv.2020
196. Wang, C,et al.Lectin-like Intestinal Defensin Inhibits 2019-nCoV Spike binding to ACE2.bioRxiv.2020
197. Li, Y,et al.Potential host range of multiple SARS-like coronaviruses and an improved ACE2-Fc variant that is potent against both SARS-CoV-2 and SARS-CoV-1.bioRxiv.2020
198. Xiong, H,et al.Robust neutralization assay based on SARS-CoV-2 S-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressed BHK21 cells.bioRxiv.2020
199. Zhang, Q,et al.SARS-CoV-2 neutralizing serum antibodies in cats: a serological investigation.bioRxiv.2020
200. Zhang, Y,et al.Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry.bioRxiv.2020
201. Liu, Y,et al.Functional and Genetic Analysis of Viral Receptor ACE2 Orthologs Reveals Broad Potential Host Range of SARS-CoV-2.bioRxiv.2020
202. Tan, X,et al.Rapid and quantitative detection of COVID-19 markers in micro-liter sized samples.bioRxiv.2020
203. Zhu, Y,et al.Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals.bioRxiv.2020
204. Walter, JD,et al.Synthetic nanobodies targeting the SARS-CoV-2 receptor-binding domain.BioRxiv.2020
205. De Assis, RR,et al.Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Plasma using a Coronavirus Antigen Microarray.BioRxiv.2020
206. Chi X,et al.Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor Binding Domain.bioRxiv.2020
207. Kim, SY,et al.Glycosaminoglycan binding motif at S1/S2 proteolytic cleavage site on spike glycoprotein may facilitate novel coronavirus (SARS-CoV-2) host cell entry.bioRxiv.2020
208. Si L,et al.Human organs-on-chips as tools for repurposing approved drugs as potential influenza and COVID19 therapeutics in viral pandemics.bioRxiv.2020
209. Liu L,et al.SARS-CoV-2 spike protein binds heparan sulfate in a length-and sequence-dependent manner.bioRxiv.2020
210. Zha L,et al.Development of a COVID-19 vaccine based on the receptor binding domain displayed on virus-like particles.bioRxiv.2020
211. Romano, M,et al.An engineered stable mini-protein to plug SARS-Cov2 Spikes.bioRxiv.2020
212. Liu, Y,et al.Functional and Genetic Analysis of Viral Receptor ACE2 Orthologs Reveals a Broad Potential Host Range of SARS-CoV-2.bioRxiv.2020
213. De Assis, RR,et al.Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Blood using a Coronavirus Antigen Microarray.BioRxiv.2020
214. Hedde, PN,et al.A Modular Microarray Imaging System for Highly Specific COVID-19 Antibody Testing.bioRxiv.2020
215. Ghazizadeh, Z,et al.Androgen regulates SARS-CoV-2 receptor levels and is associated with severe COVID-19 symptoms in men.bioRxiv.2020
216. Finch, CL,et al.Characteristic and quantifiable COVID-19-like abnormalities in CT-and PET/CT-imaged lungs of SARS-CoV-2-infected crab-eating macaques (Macaca fascicularis).bioRxiv.2020
217. Cai, Y,et al.Distinct conformational states of SARS-CoV-2 spike protein.bioRxiv.2020
218. Zang, J,et al.Immunization with the receptor–binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement.bioRxiv.2020
219. Zost, SJ,et al.Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein.bioRxiv.2020
220. Zhang, Y,et al.The ORF8 Protein of SARS-CoV-2 Mediates Immune Evasion through Potently Downregulating MHC-I.bioRxiv.2020
221. Corbett, K,et al.SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness.bioRxiv.2020
222. Yang, Y,et al.The utility of native MS for understanding the mechanism of action of repurposed therapeutics in COVID-19: heparin as a disruptor of the SARS-CoV-2 interaction with its host cell receptor.bioRxiv.2020
223. Daly, J,et al.Neuropilin-1 is a host factor for SARS-CoV-2 infection.bioRxiv.2020
224. Liu, D,et al.Ultra-sensitive nanozyme-based chemiluminescence paper test for rapid diagnosis of SARS-CoV-2 infection.bioRxiv.2020
225. Mesci, P,et al.Sofosbuvir protects human brain organoids against SARS-CoV-2.bioRxiv.2020
226. Bosco-Lauth, A,et al.Pathogenesis, transmission and response to re-exposure of SARS-CoV-2 in domestic cats.bioRxiv.2020
227. Yao, D,et al.Human H-ferritin presenting RBM of spike glycoprotein as potential vaccine of SARS-CoV-2.bioRxiv.2020
228. Liu, L,et al.A translatable subunit nanovaccine for COVID-19.Chem Rxiv.2020
229. Song, Y,et al.Discovery of Aptamers Targeting Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein.ChemRxiv.2020
230. Jiang, H,et al.Global profiling of SARS-CoV-2 specific IgG/IgM responses of convalescents using a proteome microarray.medRxiv.2020
231. Bo Diao,et al.Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.medRxiv.2020
232. Linlin Bao,et al.Reinfection could not occur in SARS-CoV-2 infected rhesus macaques.medRxiv.2020
233. Linlin Bao,et al.Rhesus macaques can be effectively infected with SARS-CoV-2 via ocular conjunctival route.medRxiv.2020
234. Ke Wang,et al.SARS-CoV-2 invades host cells via a novel route: CD147-spike protein.medRxiv.2020
235. Feng, Z,et al.The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes.medRxiv.2020
236. Wei, C,et al.Cholesterol Metabolism--Impact for SARS-CoV-2 Infection Prognosis, Entry, and Antiviral Therapies.medRxiv.2020
237. McAndrews, KM,et al.Identification of IgG antibody response to SARS-CoV-2 spike protein and its receptor binding domain does not predict rapid recovery from COVID-19.medRxiv.2020
238. Norman, M,et al.Ultra-Sensitive High-Resolution Profiling of Anti-SARS-CoV-2 Antibodies for Detecting Early Seroconversion in COVID-19 Patients.medRxiv.2020
239. Randad, PR,et al.COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in saliva.medRxiv.2020
240. Rosenberg, ES,et al.Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York.medRxiv.2020
241. Phipps, WS,et al.SARS-CoV-2 Antibody responses do not predict COVID-19 disease severity.medRxiv.2020
242. Chakraborty, S,et al.Symptomatic SARS-CoV-2 infections display specific IgG Fc structures.medRxiv.2020
243. Rosendal, E,et al.Detection of asymptomatic SARS-CoV-2 exposed individuals by a sensitive S-based ELISA..medRxiv.2020
244. Mittal, A,et al.COVID-19 Pandemic: Insights into Structure, Function, and hACE2 Receptor Recognition by the SARS-CoV-2.preprints.2020
245. Liu, L,et al.Potent Neutralizing Monoclonal Antibodies Directed to Multiple Epitopes on the SARS-CoV-2 Spike.bioRxiv.2020
246. Beddingfield, B;Iwanaga, N,et al.The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection.bioRxiv.2020
247. Salazar, E,et al.Relationship between Anti-Spike Protein Antibody Titers and SARS-CoV-2 In Vitro Virus Neutralization in Convalescent Plasma.bioRxiv.2020
248. Hanson, QM,et al.Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay.bioRxiv.2020
249. Giobbe, G,et al.SARS-CoV-2 infection and replication in human fetal and pediatric gastric organoids.bioRxiv.2020
250. Wang, N,et al.Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of COVID-19 Spike pseudotype virus.bioRxiv.2020
251. Liu, J,et al.Engineered human mesenchymal stem cells as new vaccine platform for COVID-19.bioRxiv.2020
252. Hu, J,et al.The D614G mutation of SARS-CoV-2 spike protein enhances viral infectivity and decreases neutralization sensitivity to individual convalescent sera.bioRxiv.2020
253. Klimstra, W,et al.SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected, hospitalized COVID-19 patients.bioRxiv.2020
254. den Hartog, G,et al.SARS-CoV-2-specific antibody detection for sero-epidemiology: a multiplex analysis approach accounting for accurate seroprevalence.medRxiv.2020
255. Yahalom-Ronen, Y,et al.A single dose of recombinant VSV-ΔG-spike vaccine provides protection against SARS-CoV-2 challenge.bioRxiv.2020
256. Mulgaonkar, N,et al.Bcr-Abl tyrosine kinase inhibitor imatinib as a potential drug for COVID-19.bioRxiv.2020
257. Blair, R;Vaccari, M,et al.ARDS and Cytokine Storm in SARS-CoV-2 Infected Caribbean Vervets.bioRxiv.2020
258. Walker, S,et al.SARS-CoV-2 assays to detect functional antibody responses that block ACE2 recognition in vaccinated animals and infected patients.bioRxiv.2020
259. Stukalov, A,et al.Multi-level proteomics reveals host-perturbation strategies of SARS-CoV-2 and SARS-CoV.bioRxiv.2020
260. Liu, T,et al.High-Accuracy Multiplexed SARS-CoV-2 Antibody Assay with Avidity and Saliva Capability on a Nano-Plasmonic Platform.bioRxiv.2020
261. Steiner, D,et al.Array-based analysis of SARS-CoV-2, other coronaviruses, and influenza antibodies in convalescent COVID-19 patients.bioRxiv.2020
262. Ozono, S,et al.Naturally mutated spike proteins of SARS-CoV-2 variants show differential levels of cell entry.bioRxiv.2020
263. Zhang, J,et al.Cross-reactivity of neutralizing antibody and its correlation with circulating T follicular cells in recovered COVID-19 individuals.medRxiv.2020
264. Zhou, D,et al.Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient.bioRxiv.2020
265. Zang, R,et al.Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion.bioRxiv.2020
266. Zhang, G,et al.Investigation of ACE2 N-terminal fragments binding to SARS-CoV-2 Spike RBD.bioRxiv.2020
267. Baker, AN,et al.The SARS-COV-2 spike protein binds sialic acids, and enables rapid detection in a lateral flow point of care diagnostic device.PrePrint.2020
268. Rice, A,et al.A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses.bioRxiv.2020
269. Clausen, TM,et al.SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2.bioRxiv.2020
270. Li, T,et al.A potent synthetic nanobody targets RBD and protects mice from SARS-CoV-2 infection.bioRxiv.2020
271. Pomplun, S;Jbara, M,et al.De Novo Discovery of High Affinity Peptide Binders for the SARS-CoV-2 Spike Protein.bioRxiv.2020
272. Chiuppesi, F,et al.Development of a Synthetic Poxvirus-Based SARS-CoV-2 Vaccine.bioRxiv.2020
273. Acharya, P,et al.A glycan cluster on the SARS-CoV-2 spike ectodomain is recognized by Fab-dimerized glycan-reactive antibodies.bioRxiv.2020
274. Zhang, L,et al.The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity.bioRxiv.2020
275. Onodi, F,et al.SARS-CoV-2 induces activation and diversification of human plasmacytoid pre-dendritic cells.bioRxiv.2020
276. Du, S,et al.Structures of potent and convergent neutralizing antibodies bound to the SARS-CoV-2 spike unveil a unique epitope responsible for exceptional potency.bioRxiv.2020
277. Golden, J,et al.Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease.bioRxiv.2020
278. Langellotto, F,et al.A rapidly adaptable biomaterial vaccine for SARS-CoV-2.bioRxiv.2020
279. Xiao, X,et al.Identification of potent and safe antiviral therapeutic candidates against SARS-CoV-2.bioRxiv.2020
280. Xu, C,et al.Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM.bioRxiv.2020
281. Herrmann, A,et al.A Targeted Vaccine against COVID-19: S1-Fc Vaccine Targeting the Antigen-Presenting Cell Compartment Elicits Protection against SARS-CoV-2 Infection.bioRxiv.2020
282. Routhu, N,et al.Modified Vaccinia Ankara Based SARS-CoV-2 Vaccine Expressing Full-Length Spike Induces Strong Neutralizing Antibody Response.bioRxiv.2020
283. Ke, Z,et al.Structures, conformations and distributions of SARS-CoV-2 spike protein trimers on intact virions.bioRxiv.2020
284. Zhang, Y,et al.Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins.bioRxiv.2020
Here we list part products cited in those publications.
| Cat# | Molecule | Description | Total Cites | Citation Number |
| 40591-V08H | Spike S1 | SARS-CoV-2 Spike S1 Protein, His tag, HPLC-verified | 35 | 6, 15, 33, 38, 39, 50, 59, 61, 64, 87, 91, 108, 110, 115, 116, 152, 169, 180, 186, 192, 194, 196, 200, 202, 205, 213, 232, 233, 236, 238, 254, 260, 278, 281, 284 |
| 40589-V08B1 | Spike S1+S2 ECD | SARS-CoV-2 Spike S1+S2 ECD Protein, His tag | 34 | 23, 25, 39, 73, 87, 96, 98, 105, 109, 110, 115, 183, 185, 192, 200, 204, 205, 206, 209, 213, 221, 229, 236, 239, 251, 258, 261, 264, 269, 273, 273, 276, 282, 284 |
| 40592-V05H | Spike RBD | SARS-CoV-2 Spike RBD Protein, mFc tag, HPLC-verified | 19 | 8, 16, 21, 26, 32, 61, 143, 168, 179, 192, 198, 204, 205, 206, 213, 218, 219, 227, 229 |
| 40588-V08B | NP-CoV | SARS-CoV-2 NP-CoV Protein, His tag | 19 | 64, 83, 96, 109, 110, 111, 118, 119, 155, 180, 185, 187, 192, 205, 213, 239, 241, 254, 278 |
| 40592-V08B | Spike RBD | SARS-CoV-2 Spike RBD Protein, His tag | 18 | 23, 25, 31, 32, 50, 61, 77, 83, 115, 150, 169, 206, 229, 254, 261, 266, 269, 276 |
| 40150-V08B1 | Spike S1 | SARS-CoV Spike S1 Protein, His tag | 18 | 16, 24, 39, 47, 110, 115, 116, 150, 159, 180, 192, 194, 203, 205, 206, 213, 248, 263 |
| 40590-V08B | Spike S2 | SARS-CoV-2 Spike S2 Protein, His tag | 12 | 43, 54, 83, 87, 110, 192, 203, 205, 213, 261, 263, 278 |
| 40592-V08H | Spike RBD | SARS-CoV-2 Spike RBD Protein, His tag | 11 | 87, 108, 109, 110, 116, 118, 211, 237, 239, 256, 260 |
| 10108-H08H | ACE2 | Human ACE2 Protein, His tag, HPLC-verified | 10 | 21, 24, 29, 32, 61, 173, 206, 227, 229, 248 |
| 40150-V08B2 | Spike RBD | SARS-CoV Spike RBD Protein, His tag | 9 | 21, 32, 110, 192, 203, 205, 213, 224, 261 |
| 40143-V08B | NP-CoV | SARS-CoV NP-CoV Protein, His tag | 7 | 47, 51, 68, 110, 192, 205, 213 |
| 40591-V02H | Spike S1 | SARS-CoV-2 Spike S1 Protein, Fc tag | 7 | 95, 157, 192, 201, 205, 212, 213 |
| 40600-V08H | Spike S1 | HCoV-NL63 Spike S1 Protein, His tag | 7 | 48, 110, 147, 153, 192, 205, 213 |
| 40601-V08H | Spike S1 | HCoV-229E Spike S1 Protein, His tag | 7 | 48, 110, 147, 153, 192, 205, 213 |
| 40069-V08B | Spike S1+S2 ECD | MERS-CoV Spike S1+S2 ECD Protein, His tag | 7 | 101, 110, 183, 192, 205, 213, 264 |
| 40071-V08B1 | Spike RBD | MERS-CoV Spike RBD Protein, His tag | 7 | 110, 150, 192, 205, 213, 224, 261 |
| 40607-V08B | Spike S1+S2 ECD | HCoV-OC43 Spike S1+S2 ECD Protein, His tag | 7 | 141, 192, 205, 213, 224, 261, 264 |
| 40069-V08H | Spike S1 | MERS-CoV Spike S1 Protein, His tag | 6 | 59, 110, 192, 194, 205, 213 |
| 40605-V08B | Spike S1+S2 ECD | HCoV-229E Spike S1+S2 ECD Protein, His tag | 6 | 110, 192, 205, 213, 239, 261 |
| 40069-V08B1 | Spike S1 | MERS-CoV Spike S1 Protein, His tag | 6 | 110, 192, 205, 213, 261, 263 |
| 40021-V08H | Spike S1 | HCoV-HKU1 Spike S1 Protein, His tag | 5 | 110, 153, 192, 205, 213 |
| 40070-V08B | Spike S2 | MERS-CoV Spike S2 Protein, His tag | 5 | 110, 192, 205, 213, 263 |
| 40602-V08H | Spike S1 | HCoV-HKU1 Spike S1 Protein, His tag | 5 | 110, 150, 192, 205, 213 |
| 40606-V08B | Spike S1+S2 ECD | HCoV-HKU1 Spike S1+S2 ECD Protein, His tag | 5 | 192, 205, 213, 224, 261 |
| 10108-H02H | ACE2 | Human ACE2 Protein, Fc tag | 5 | 49, 106, 196, 246, 252 |
| 10108-H05H | ACE2 | Human ACE2 Protein, Fc tag | 5 | 24, 77, 161, 169, 258 |
| 40591-V08B1 | Spike S1 | SARS-CoV-2 Spike S1 Protein, His tag | 6 | 24, 110, 236, 261, 263 |
| 40150-V31B2 | Spike RBD | SARS-CoV Spike RBD Protein, rFc Tag | 4 | 192, 194, 205, 213 |
| 40068-V08B | NP-CoV | MERS-CoV NP-CoV Protein, His tag | 4 | 110, 192, 205, 213 |
| 40524-V08E | PLpro | SARS-CoV PLpro Protein, His tag | 4 | 110, 192, 205, 213 |
| 40603-V08H | HE-CoV | HCoV-OC43 HE-CoV Protein, His tag | 4 | 110, 192, 205, 213 |
| 10003-V06H1 | HA1 | H5N1 HA1 Protein, His & Fc Tag | 3 | 192, 205, 213 |
| 10003-V06H3 | HA1 | H5N1 HA1 Protein, His & Fc Tag | 3 | 192, 205, 213 |
| 11049-V08B | RSV-F | RSV RSV-F Protein, His tag | 3 | 192, 205, 213 |
| 11070-V08H | RSV-G | RSV RSV-G Protein, His tag | 3 | 192, 205, 213 |
| 11716-V08H | HA1 | Influenza B HA1 Protein, His tag | 3 | 192, 205, 213 |
| 11716-V08H1 | HA1 | Influenza B HA1 Protein, His tag | 3 | 192, 205, 213 |
| 13029-V08H | RSV-G | RSV RSV-G Protein, His tag | 3 | 192, 205, 213 |
| 40035-V08H | HA1 | H1N1 HA1 Protein, His tag | 3 | 192, 205, 213 |
| 40035-V08H1 | HA1 | H1N1 HA1 Protein, His tag | 3 | 192, 205, 213 |
| 40037-V08B | RSV-F | RSV RSV-F Protein, His tag | 3 | 192, 205, 213 |
| 40071-V05B | Spike RBD | MERS-CoV Spike RBD Protein, mFc Tag | 3 | 192, 205, 213 |
| 40071-V31B | Spike RBD | MERS-CoV Spike RBD Protein, rFc Tag | 3 | 192, 205, 213 |
| 40071-V31B1 | Spike RBD | MERS-CoV Spike RBD Protein, rFc Tag | 3 | 192, 205, 213 |
| 40103-V08H | HA1 | H7N9 HA1 Protein, His tag | 3 | 192, 205, 213 |
| 40103-V08H1 | HA1 | H7N9 HA1 Protein, His tag | 3 | 192, 205, 213 |
| 40354-V08B | HA1 | H3N2 HA1 Protein, His tag | 3 | 192, 205, 213 |
| 40354-V08H1 | HA1 | H3N2 HA1 Protein, His tag | 3 | 192, 205, 213 |
| 40458-V08B | DcCoV-NP | DcCoV DcCoV-NP Protein, His tag | 3 | 192, 205, 213 |
| 40498-V08B | HA | Influenza B HA Protein, His tag | 3 | 192, 205, 213 |
| 40498-V08H1 | HA | Influenza B HA Protein, His tag | 3 | 192, 205, 213 |
| 40591-V05H1 | Spike S1 | SARS-CoV-2 Spike S1 Protein, mFc Tag | 3 | 192, 205, 213 |
| 40604-V08B | Spike S1+S2 ECD | HCoV-NL63 Spike S1+S2 ECD Protein, His tag | 3 | 192, 205, 213 |
| 40592-V08B-B | Spike RBD | SARS-CoV-2 Spike RBD Protein, His tag | 3 | 23, 25, 174 |
| 40634-V08B | Spike S1+S2 ECD | SARS-CoV Spike S1+S2 ECD Protein, His tag | 3 | 183, 261, 264 |
| 10108-H08B | ACE2 | Human ACE2 Protein, His tag, HPLC-verified | 2 | 25, 270 |
| 40592-V02H | Spike RBD | SARS-CoV-2 Spike RBD Protein, Fc tag | 2 | 215, 248 |
| 10108-H08H-B | ACE2 | human ACE2 His tag, Biotinylated | 2 | 161, 282 |
| 40592-V08H6 | Spike RBD Mutant | SARS-CoV-2 Spike RBD Mutant (F342L),His tag | 2 | 24, 150 |
| 40592-V08H7 | Spike RBD Mutant | SARS-CoV-2 Spike RBD Mutant (K458R),His tag | 2 | 24, 150 |
| 10602-HNAE | TNF | Human TNF native | 1 | 64 |
| 40592-V31H | Spike RBD | SARS-CoV-2 Spike RBD rFc Tag | 1 | 77 |
| 10395-HNAE | IL6 | human IL6 native | 1 | 91 |
| 11055-V08B | HA | H1N1 HA His tag | 1 | 92 |
| 11056-V08B | HA | H3N2 HA His tag | 1 | 93 |
| 11692-V08B | HA | H1N1 HA His tag | 1 | 94 |
| 10690-MNAH | IGHG1 | mouse IGHG1 Mouse IgG1-Fc Protein (102 Cys/Ser) | 1 | 113 |
| 11055-V08H4 | HA1 | H1N1 HA1 His Tag (A/California/04/2009) | 1 | 115 |
| 11675-V08B | HA | H1N1 HA His Tag | 1 | 116 |
| 40589-V27B-B | Spike S1+S2 ECD | SARS-CoV-2 Spike S1+S2 ECD AVI & His tag, Biotinylated | 1 | 123 |
| 40592-V08H1 | Spike RBD Mutant | SARS-CoV-2 Spike RBD Mutant (V367F), His tag | 1 | 127 |
| 40592-V08H2 | Spike RBD Mutant | SARS-CoV-2 Spike RBD Mutant (N354D), His tag | 1 | 128 |
| 40592-V08H4 | Spike RBD Mutant | SARS-CoV-2 Spike RBD Mutant (A435S), His tag | 1 | 129 |
| 40592-V08H5 | Spike RBD Mutant | SARS-CoV-2 Spike RBD Mutant (V483A), His tag | 1 | 130 |
| 40592-V08H8 | Spike RBD Mutant | SARS-CoV-2 Spike RBD Mutant (G476S),His tag | 1 | 131 |
| 40592-V08H9 | Spike RBD Mutant | SARS-CoV-2 Spike RBD Mutant (W436R),His tag | 1 | 132 |
| 40593-V07E | PLpro | SARS-CoV-2 PLpro His tag | 1 | 133 |
| 40598-V07E | CoV-ME | SARS-CoV-2 CoV-ME His tag | 1 | 134 |
| 40643-V07E | NP-CoV | HCoV-OC43 NP-CoV His tag | 1 | 135 |
| 90211-C02H | ACE2 | Rhesus ACE2 Fc Tag | 1 | 136 |
| Cat# | Description | Antigen | Type | Total Cites | Citation Number |
| 40150-R007 | SARS-CoV-2 Spike Antibody | Spike | Rabbit MAb | 14 | 2, 31, 45, 59, 90, 99, 138, 142, 151, 169, 188, 196, 234, 253 |
| 40143-R019 | SARS-CoV-2 NP-CoV Antibody | NP-CoV | Rabbit MAb | 11 | 17, 28, 82, 90, 107, 138, 154, 184, 225, 235, 253 |
| 40143-R001 | SARS-CoV NP-CoV Antibody | NP-CoV | Rabbit MAb | 10 | 57, 69, 116, 117, 139, 166, 180, 231, 243, 247 |
| 40143-MM05 | SARS-CoV Nucleocapsid Antibody | Nucleocapsid | Mouse MAb | 8 | 19, 52, 180, 181, 249, 275, 277, 283 |
| 40143-T62 | SARS-CoV NP-CoV Antibody | NP-CoV | Rabbit PAb | 7 | 10, 27, 57, 58, 60, 67, 109 |
| 40592-T62 | SARS-CoV-2 Spike RBD Antibody | Spike RBD | Rabbit PAb | 7 | 11, 118, 223, 237, 239, 265, 282 |
| 40150-T62 | SARS-CoV Spike S1 Antibody | Spike S1 | Rabbit PAb | 6 | 37, 81, 162, 244, 272, 277 |
| 40150-D001 | SARS-CoV Spike Antibody | Spike | Chimeric MAb | 6 | 31, 45, 116, 151, 208, 273 |
| 40150-T52 | SARS-CoV Spike Antibody | Spike | Rabbit PAb | 5 | 31, 75, 79, 193, 194 |
| 40150-RP01 | SARS-CoV Spike S1 Antibody | Spike S1 | Rabbit PAb | 4 | 31, 167, 174, 194 |
| 40591-MM43 | SARS-CoV-2 Spike Antibody | Spike | Neutralizing Antibody, Mouse Mab | 4 | 115, 116, 140, 151 |
| 40592-MM57 | SARS-CoV-2 Spike Antibody | Spike | Neutralizing Antibody, Mouse Mab | 4 | 115, 131, 146, 151 |
| 10108-RP01 | HIV Gag-p24 Antibody | ACE2 | Rabbit PAb | 3 | 62, 227, 235 |
| 40150-D003 | SARS-CoV-2 Spike Antibody | Spike | Chimeric Mab | 3 | 116, 151, 268 |
| 40150-T62-CoV2 | SARS Spike Antibody | Spike | Rabbit PAb | 3 | 28, 109, 136 |
| 40588-T62 | SARS-CoV-2 NP-CoV Antibody | NP-CoV | Rabbit PAb | 3 | 118, 120, 187 |
| 40150-MM02 | SARS-CoV Spike S1 Antibody | Spike S1 | Mouse MAb | 2 | 37, 281 |
| 40590-T62 | SARS-CoV-2 Spike S2 Antibody | Spike S2 | Rabbit PAb | 2 | 184, 265 |
| 10108-T56 | Human ACE2 Antibody | ACE2 | Rabbit PAb | 1 | 63 |
| 11695-RP01 | HIV Gag-p24 Antibody | Gag-p24 | Rabbit PAb | 1 | 65 |
| 11973-MM05T-H | M13 Antibody | M13 | Mouse MAb | 1 | 66 |
| 40068-MM10 | MERS-CoV NP-CoV Antibody | NP-CoV | Mouse MAb | 1 | 67 |
| 40068-RP02 | MERS-CoV NP-CoV Antibody | NP-CoV | Rabbit PAb | 1 | 68 |
| 40070-MM11 | MERS-CoV Spike s2 Antibody | Spike s2 | Mouse MAb | 1 | 69 |
| HG1K | Human IgG1, kappa Isotype Control | 1 | 81 | ||
| SSA009 | Goat Anti-Human IgG Secondary Antibody (Biotin) | Secondary Antibody | 1 | 84 | |
| 11048-MM06 | H5N1 HA Antibody | HA | Mouse MAb | 1 | 114 |
| 11684-T62 | H1N1 HA Antibody | HA | Rabbit Pab | 1 | 117 |
| 11973-MM05T-H | M13 Antibody | M13 | Mouse MAb | 1 | 118 |
| 40143-MM08 | SARS-CoV-2 NP-CoV Antibody | NP-CoV | Mouse Mab | 1 | 119 |
| 40143-R004 | SARS-CoV-2 NP-CoV Antibody | NP-CoV | Rabbit Mab | 1 | 120 |
| 40150-D002 | SARS-CoV-2 Spike Antibody | Spike | Chimeric Mab | 1 | 121 |
| 40150-D006 | SARS-CoV-2 Spike Antibody | Spike | Chimeric Mab | 1 | 122 |
| 40590-D001 | SARS-CoV-2 Spike S2 Antibody | Spike S2 | Chimeric Mab | 1 | 124 |
| 40592-MP01 | SARS-CoV-2 Spike RBD Antibody | Spike RBD | Mouse Pab | 1 | 126 |
| SSA003 | Goat Anti-Rabbit IgG-Fc Secondary Antibody (HRP) | Secondary Antibody | 1 | 137 | |
| SSA004 | Goat Anti-Rabbit IgG Secondary Antibody (HRP) | Secondary Antibody | 1 | 138 |
